Investors might want to bet on Akcea Therapeutics (AKCA), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...
One stock that might be an intriguing choice for investors right now is Akcea Therapeutics, Inc. AKCA. This is because this security in the Medical - Biomedical and Genetics space is seeing solid ...
Wall Street expects a year-over-year increase in earnings on higher revenues when Akcea Therapeutics (AKCA) reports results for the quarter ended June 2019. While this widely-known consensus outlook ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results